Literature DB >> 17385022

Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variability.

Ying Hong1, Donald E Mager, Robert A Blum, William J Jusko.   

Abstract

PURPOSE: To develop a population pharmacokinetic/pharmacodynamic (PK/PD) model that characterizes the effects of major systemic corticosteroids on lymphocyte trafficking and responsiveness.
MATERIALS AND METHODS: Single, presumably equivalent, doses of intravenous hydrocortisone (HC), dexamethasone (DEX), methylprednisolone (MPL), and oral prednisolone (PNL) were administered to five healthy male subjects in a five--way crossover, placebo--controlled study. Measurements included plasma drug and cortisol concentrations, total lymphocyte counts, and whole blood lymphocyte proliferation (WBLP). Population data analysis was performed using a Monte Carlo-Parametric Expectation Maximization algorithm.
RESULTS: The final indirect, multi-component, mechanism-based model well captured the circadian rhythm exhibited in cortisol production and suppression, lymphocyte trafficking, and WBLP temporal profiles. In contrast to PK parameters, variability of drug concentrations producing 50% maximal immunosuppression (IC(50)) were larger between subjects (73-118%). The individual log-transformed reciprocal posterior Bayesian estimates of IC(50) for ex vivo WBLP were highly correlated with those determined in vitro for the four drugs (r ( 2 ) = 0.928).
CONCLUSIONS: The immunosuppressive dynamics of the four corticosteroids was well described by the population PK/PD model with the incorporation of inter-occasion variability for several model components. This study provides improvements in modeling systemic corticosteroid effects and demonstrates greater variability of system and dynamic parameters compared to pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17385022      PMCID: PMC4181339          DOI: 10.1007/s11095-006-9232-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

Review 1.  Molecular mechanisms of glucocorticoid action: what is important?

Authors:  R Newton
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

2.  Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.

Authors:  Jeffrey G Stark; Sybille Werner; Susanne Homrighausen; Yufei Tang; Michael Krieg; Hartmut Derendorf; Helmut Moellmann; Guenther Hochhaus
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-22       Impact factor: 2.745

3.  Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics.

Authors:  Donald E Mager; Sheren X Lin; Robert A Blum; Christian D Lates; William J Jusko
Journal:  J Clin Pharmacol       Date:  2003-11       Impact factor: 3.126

Review 4.  Ex vivo analysis of T-cell function.

Authors:  Maria A Suni; Vernon C Maino; Holden T Maecker
Journal:  Curr Opin Immunol       Date:  2005-08       Impact factor: 7.486

5.  Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking.

Authors:  M A Milad; E A Ludwig; S Anné; E Middleton; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1994-12

6.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

7.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

8.  Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation.

Authors:  Mindy He Magee; Robert A Blum; Christian D Lates; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

9.  Prednisolone pharmacodynamics: leukocyte trafficking in the rat.

Authors:  J A Wald; W J Jusko
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

10.  Altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism.

Authors:  Yuen Yi Hon; William J Jusko; Vicky E Spratlin; Michael W Jann
Journal:  J Clin Pharmacol       Date:  2006-04       Impact factor: 3.126

View more
  9 in total

1.  Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.

Authors:  Noureddine Hamitouche; Emmanuelle Comets; Mégane Ribot; Jean-Claude Alvarez; Eric Bellissant; Bruno Laviolle
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

Review 2.  Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming.

Authors:  Diane R Mould; Richard N Upton; Jessica Wojciechowski; Becky L Phan; Stacy Tse; Marla C Dubinsky
Journal:  AAPS J       Date:  2018-06-14       Impact factor: 4.009

Review 3.  Pharmacokinetic/pharmacodynamic modeling in inflammation.

Authors:  Hoi-Kei Lon; Dongyang Liu; William J Jusko
Journal:  Crit Rev Biomed Eng       Date:  2012

Review 4.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

5.  Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans.

Authors:  Cheng Chang; Wonkyung Byon; Yifeng Lu; Leslie K Jacobsen; Lori L Badura; Aarti Sawant-Basak; Emily Miller; Jing Liu; Sarah Grimwood; Ellen Q Wang; Tristan S Maurer
Journal:  AAPS J       Date:  2011-08-17       Impact factor: 4.009

6.  Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone.

Authors:  Jian Xu; Julia Winkler; Sreedharan Nair Sabarinath; Hartmut Derendorf
Journal:  AAPS J       Date:  2008-06-25       Impact factor: 4.009

Review 7.  Scaling pharmacodynamics from in vitro and preclinical animal studies to humans.

Authors:  Donald E Mager; Sukyung Woo; William J Jusko
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

8.  Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol.

Authors:  Pablo Morentin Gutierrez; James Yates; Catarina Nilsson; Sue Birtles
Journal:  Pharmacol Res Perspect       Date:  2019-03-09

9.  Prednisolone in Dogs-Plasma Exposure and White Blood Cell Response.

Authors:  Carl Ekstrand; Helena Pettersson; Ronette Gehring; Mikael Hedeland; Sara Adolfsson; Inger Lilliehöök
Journal:  Front Vet Sci       Date:  2021-06-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.